Search
Mequinol
go.drugbank.com/drugs/DB09516ApprovedWithdrawnIt is used as an inhibitor for acrylic monomers and acrylonitirles, as a stabilizer for chlorinated hydrocarbons and ethyl cellulose, as an ultraviolet inhibitor, as a chemical intermediate in the manufacture … It is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment of solar lentigines.
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. It was jointly discovered and developed by Protagonist and Johnson & Johnson and provides a novel, oral treatment option for patie...
Malathion
go.drugbank.com/drugs/DB00772ApprovedMalathion is an irreversible cholinesterase inhibitor and has low human toxicity. … Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: O,O-dimethyl S-1,2-di(ethoxycarbamyl)ethylLB-P8
go.drugbank.com/drugs/DB18535InvestigationalLB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … [L44256] IDH1 mutations are common in different types of cancer, such as gliomas, AML, intrahepatic cholangiocarcinoma, chondrosarcoma, and myelodysplastic syndromes (MDS), and they lead to an increase
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsPodophyllin
go.drugbank.com/drugs/DB09094ApprovedPodophyllin is a resin extracted from the roots of Podophyllum peltatum (American mandrake) and Podophyllum emodi, which contains numerous compounds, amongst which is podophyllin (as well as the drug podophyllotoxin). Podophyllin is the ...
Mixtures: Canthacur-PS, CANTHACUR PS %1,%5,%30 TOPIKAL SOLUSYON 7,5 MLIndomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationalNSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole … superficial punctate keratitis and subjective symptoms of discomfort, including pain, burning or pricking, or a tingling sensation after instillation into the cul‐de‐sac.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acidAlprenolol
go.drugbank.com/drugs/DB00866ApprovedWithdrawnOne of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates